Combined Therapy of Low-Dose Angiotensin Receptor-Neprilysin Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

• Asıl Yazarlar: Donghyun Kim (Yazar), Gyuho Jang (Yazar), Jaetaek Hwang (Yazar), Xiaofan Wei (Yazar), Hyunsoo Kim (Yazar), Jinbae Son (Yazar), Sang-Jae Rhee (Yazar), Kyeong-Ho Yun (Yazar), Seok-Kyu Oh (Yazar), Chang-Myung Oh (Yazar), Raekil Park (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2022-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Although cancer-therapy-related cardiac dysfunction (CTRCD) is a critical issue in clinical practice, there is a glaring lack of evidence regarding cardiotoxicity management. To determine an effective and suitable dosage of treatment using angiotensin receptor-neprilysin inhibitors (ARNI) with sodiu...